fashion -WSS

fashion

author：explore 2025-09-29 22:46:28 - browse：757

Chief executive officer of Sanofi Paul Hudson, wearing glasses, speaks into a mic — pharma coverage from STAT — Sanofi CEO Paul Hudson Carolyn Kaster/AP

LONDON — Sanofi CEO Paul Hudson on Wednesday defended his company’s recent moves to abandon future profit guidance and up its investment in its own research programs, arguing that the dramatically negative market response didn’t reflect the potential rewards that could stem from the plan.

“Would I have liked the stock market reaction to be more generous? Of course,” Hudson said at a Financial Times event in London. “But this is a long-term game, and if you’re trying to deliver long-term value, you try not to make too many short-term decisions.”

Sanofi unveiled its R&D plans late last month as it announced its third-quarter performance and said that it was spinning out its consumer health division. As the company said it was going to spend more money on research, it also withdrew earnings outlooks for 2025. Company executives have argued that this was the moment — when Sanofi has a strong pipeline and isn’t facing patent expirations for years — to increase its R&D resources, even at the expense of short-term profits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： VC firm RA Capital starts a new synthetic biology incubator

hotspot

WSS

An outrageous hospital charge: I paid $710 for an hour of babysitting

Paxlovid study fails to answer questions over benefit for broader groups

Stoke drug shows lower activity against childhood epilepsy

WATCH: Why do fingernails fall off when they're damaged?

The battle over the Brookhaven Landfill on Long Island

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

entertainment

fashion

focus

The high cost of giving birth even with insurance

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Medical leaders decry Supreme Court decision on affirmative action

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Timeline: Special counsel's probe into Trump's handling of classified documents

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Biden to sign 'historic' executive order on how US military handles sexual assault cases

Cancer drug shortages should be causing more outrage

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

Wikipedia

Disclosing genetic information: not as worrisome as once feared

Why we need to separate burnout from moral injury in health care

Will biotech layoffs continue through 2023?

Will biotech layoffs continue through 2023?

Trump allegedly attempted to have surveillance video deleted: Special Counsel

Why are elite athletes different? Take a look at their microbes

knowledge

explore

hotspot

knowledge